Results 71 to 80 of about 136,281 (235)
Abstract BACKGROUND Atopic dermatitis (AD) is increasingly recognized as a systemic inflammatory disorder linked to intestinal immune and microbiome dysregulation. However, whether dietary galactomannan fibers can mitigate AD through coordinated modulation of the gut–skin axis remains unexplored.
Derrick Kakooza +6 more
wiley +1 more source
Rademikibart, a potent IL‐4Rα‐targeting antibody, achieved its primary endpoint as a treatment for adults with moderate‐to‐severe atopic dermatitis (AD) in the CBP‐201‐WW001 Phase 2 trial. There is a need for AD treatment options with convenient dosing intervals.
Jonathan I. Silverberg +2 more
wiley +1 more source
Interplay of Staphylococcal and Host Proteases Promotes Skin Barrier Disruption in Netherton Syndrome. [PDF]
Netherton syndrome (NS) is a monogenic skin disease resulting from loss of function of lymphoepithelial Kazal-type-related protease inhibitor (LEKTI-1).
Butcher, Anna M +12 more
core
In adults with atopic dermatitis and chronic pruritus, the mental comorbidity of Somatic Symptom Disorder is associated with higher average and worst pruritus intensity, higher psychological distress and lower quality of life. Additionally, there were nonsignificant changes in cutaneous nerve fiber densities in skin biopsies.
Stefan M. Kahnert +13 more
wiley +1 more source
Comparing Self‐Reported and Physician‐Assessed Acne Severity Using Real‐World Data
ABSTRACT Background Real‐world data (RWD) offers access to vast amounts of health information; however, limited knowledge exists regarding its reliability in clinical and research practices. Objectives To analyse the agreement between self‐assessed severity of self‐reported acne vulgaris (AV), and physician‐assessed severity based on photographic ...
Ali Al‐Mousawi +7 more
wiley +1 more source
We surveyed 290 paediatric patients with atopic dermatitis (AD)/their caregivers to determine troublesome AD features described as PROs. The most selected were itch (0‐ to 5‐year‐old children: 85%; children aged ≥ 6 years: 89.3%), skin appearance/condition (69.9% and 61.6%, respectively), and sleep disturbance (38.1% and 25.4%, respectively ...
Yuji Fujita +10 more
wiley +1 more source
Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson +4 more
wiley +1 more source
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won +11 more
wiley +1 more source
JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series
ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni +6 more
wiley +1 more source
Juvenile Mycosis Fungoides: A Multicenter Retrospective Italian Study
This multicenter retrospective study included 29 juvenile mycosis fungoides (JMF) patients from five Italian centres with confirmed histopathological diagnosis. most often presents with hypopigmented/classic variants and CD8+ phenotype. Early‐onset cases ( < 14 years) show better long‐term outcomes.
Andrea Michelerio +8 more
wiley +1 more source

